EyePoint Pharmaceuticals (EYPT) announced the appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer to succeed Dario Paggiarino, M.D. who has served as EyePoint’s Chief Medical Officer since 2016. Dr. Ribeiro joins EyePoint from Apellis Pharmaceuticals (APLS), where he served as Vice President and Head of Clinical Development.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EYPT:
- EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
- EYPT Upcoming Earnings Report: What to Expect?
- EyePoint reports inducement grants under Nasdaq listing rule
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint price target raised to $39 from $30 at Mizuho
